Cinnarizin, tablets 25 mg 56 pcs

Selective blocker of “slow” calcium channels, reduces the entry of calcium ions into cells and decreases their content in the plasma membrane depot, reduces the tone of arteriolar smooth muscle. By directly affecting the vascular smooth muscle, it reduces their response to biogenic substances (adrenaline, noradrenaline, dopamine, angiotensin, vasopressin).

The drug is absorbed in the stomach and intestine. The maximum concentration in blood plasma after oral administration is 1-3 hours. Binding of cinnarizine with plasma proteins is 91%. It is fully metabolized in the liver (via dealkylation). The elimination half-life is 4 hours. It is excreted as metabolites: 1/3 – by kidneys and 2/3 – with feces – by intestine.

.

Indications

Symptoms of cerebrovascular insufficiency (dizziness, tinnitus, headache, memory impairment, decreased concentration);
vestibular disorders (including Meniere’s disease; dizziness, tinnitus, nystagmus, nausea and vomiting of labyrinthine origin);
prevention of kinetosis (“road sickness” – sea and air sickness);
migraine (prevention of attacks);
peripheral circulatory disorders: Raynaud’s disease, intermittent claudication, acrocyanosis, trophic disorders (including trophic and varicose ulcers).

Pharmacological effect

A selective blocker of “slow” calcium channels, reduces the entry of calcium ions into cells and reduces their content in the plasmalemma depot, reduces the tone of the smooth muscles of arterioles. Directly affecting the smooth muscles of blood vessels, it reduces their response to nutrients (adrenaline, norepinephrine, dopamine, angiotensin, vasopressin).

The drug is absorbed in the stomach and intestines. The maximum concentration in blood plasma after oral administration is 1-3 hours. The binding of cinnarizine to plasma proteins is 91%. Completely metabolized in the liver (via dealkylation). The half-life is 4 hours. Excreted in the form of metabolites: 1/3 – by the kidneys and 2/3 – with feces – in the intestines.

Special instructions

For patients suffering from Parkinson’s disease, the drug should be prescribed only when the benefits of treatment outweigh the possible worsening of the underlying disease.
Due to the antihistamine effect, the drug should be discontinued 4 days before the allergic skin test.

The drug may affect the results of anti-doping control of athletes (false positive result).
Patients with lactose intolerance should take into account that it is part of the drug.
With long-term use, it is recommended to conduct a control laboratory study of the function of the liver, kidneys, and peripheral blood.

During treatment with the drug you should refrain from drinking alcohol.

The ability to influence the speed of reactions when driving vehicles or working with other mechanisms

Drowsiness may develop, especially at the beginning of treatment, so care should be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Cinnarizine

Composition

1 tablet contains:
active substance:
cinnarizine – 0.025 g
excipients:
potato starch – 0.0178 g
lactose (milk sugar) – 0.102 g
medium molecular weight povidone – 0.0030 g
colloidal silicon dioxide (aerosil) – 0.0007 g
magnesium stearate – 0.0015 g

Pregnancy

The use of the drug during pregnancy is contraindicated. While taking the drug
breastfeeding should be stopped.

Contraindications

Hypersensitivity, pregnancy, lactation.

Lactose intolerance,

lactase deficiency,

glucose-galactose malabsorption syndrome.

Children under 5 years old.

With caution

Parkinson’s disease.

Side Effects

From the nervous system: drowsiness, fatigue, headache, extrapyramidal disorders (tremor of the limbs and increased muscle tone, hypokinesia), depression. From the digestive system: dry mouth, pain in the epigastric region, dyspepsia, cholestatic jaundice.

Interaction

With the combined use of Cinnarizine and ethanol (or ethanol-containing drugs), antihypertensives, nootropic and vasodilators, and other drugs that have a depressant effect on the central nervous system (tricyclic antidepressants, hypnotics, sedatives), an increase in their effect is observed.

Overdose

Symptoms: vomiting, drowsiness, tremor, decreased blood pressure, coma.
Treatment: there is no specific antidote, gastric lavage, taking activated charcoal, symptomatic therapy.

Storage conditions

In a dry place, protected from light

Shelf life

3 years.

Manufacturer

Update of PFC JSC, Russia